Goldman Sachs Group Inc Ionis Pharmaceuticals Inc Call Options Transaction History

Goldman Sachs Group Inc

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 13, 2024	BUY	$36.45 - $47.7 $1.15 Million - $1.5 Million	31,500 Added 262.5%	43,500 $2.07 Million
Q1 2024 May 15, 2024	SELL	$42.03 - $53.55 $756,540 - $963,900	-18,000 Reduced 60.0%	12,000 $520,000
Q4 2023 Feb 13, 2024	BUY	$43.39 - $51.63 $915,529 - $1.09 Million	21,100 Added 237.08%	30,000 $1.52 Million
Q3 2023 May 14, 2024	SELL	$38.5 - $47.13 $812,350 - $994,443	-21,100 Reduced 70.33%	8,900 $403,000
Q3 2023 Nov 14, 2023	BUY	$38.5 - $47.13 $342,650 - $419,457	8,900 New	8,900 $403,000
Q4 2022 May 14, 2024	SELL	$37.12 - $46.52 $185,600 - $232,600	-5,000 Reduced 16.67%	25,000 $944,000
Q4 2022 Feb 13, 2023	BUY	$37.12 - $46.52 $927,999 - $1.16 Million	25,000 New	25,000 $944,000

389

125M

2.25M

510K

Ticker IONS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,940,992
Market Cap $5.45B
Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.